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Atopic dermatitis (AD) displays different clinical symptoms, progress, and response to treatment during
early infancy and after childhood. After the childhood period, itch appears ﬁrst, followed by formation of
well-circumscribed plaque or polymorphous dermatoses at the same site. When accompanied with
dermatitis and dry skin, treatment of skin lesions should be prioritized. When itch appears ﬁrst, disease
history, such as causes and time of appearance of itch should be obtained by history taking. In many
cases, itch increases in the evening when the sympathetic nerve activity decreased. Treatment is pro-
vided considering that hypersensitivity to various external stimulations can cause itch. Heat and
sweating are thought to especially exacerbate itch. Factors causing itch, such as cytokines and chemical
messengers, also induce itch mainly by stimulating the nerve. Scratching further aggravates dermatitis.
Skin hypersensibility, where other non-itch senses, such as pain and heat, are felt as itch, sometimes
occurs in AD. Abnormal elongation of the sensory nerve into the epidermis, as well as sensitizing of the
peripheral/central nerve, are possible causes of hypersensitivity, leading to itch. To control itch induced
by environmental factors such as heat, treatment for dermatitis is given priority. In the background of
itch exacerbated by sweating, attention should be given to the negative impact of sweat on skin ho-
meostasis due to 1) leaving excess sweat on the skin, and 2) heat retention due to insufﬁcient sweating.
Excess sweat on the skin should be properly wiped off, and dermatitis should be controlled so that
appropriate amount of sweat can be produced. Not only stimulation from the skin surface, but also visual
and auditory stimulation can induce new itch. This “contagious itch” can be notably observed in patients
with AD. This article reviews and introduces causes of aggravation of itch and information regarding how
to cope with such causes.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Clinical features of itch in atopic dermatitis (AD)
Clinical characteristics of AD change with both age and disease
duration. Sulzberger, who ﬁrst named AD, described patients with
AD according to a characteristic clinical picture for each age.1
Clinical manifestation of AD in the childhood period centers on
eczematous change accompanied with serous papules (Fig. 1).
Eczema or exudative papules are accompanied by strong itch, and
excoriation and new papules develop due to scratching (Fig. 1).
Next, as clinical course progresses from childhood to adult, skin
lesions begin to change into a different phenotype than that in the
childhood period (Fig. 1). Phenotype of dermatitis during this
period is more varied, and this condition has been historicallyology, Course of Integrated
ersity, 2-2 Yamadaoka, Suita,
jp (H. Murota).
ety of Allergology.
rgology. Production and hosting by Elsereferred to as disseminated neurodermatitis, or Besnier's prurigo.2,3
Disseminated neurodermatitis was proposed by Brocq and Jac-
quet.2 Characteristics include, 1) mental nervousness, 2) contin-
uous itch appearing before visible skin abnormality, 3) apparent
circumscribed plaque occurring in almost completely same site
where the itch ﬁrst appeared, 4) distribution of skin lesions similar
to dermatoses of nervous origin, 5) skin dryness, 6) visible papillae
of hypertrophy of skin and pigmented skin, and 7) chronic condi-
tion. Besnier's prurigo was proposed by Besnier, and determined as
a type of “diathetic prurigo”.3 Skin manifestation in early infancy is
characterized by non-speciﬁc skin lesions occurring after the
appearance of itch, and in the young adulthood period, it is char-
acterized by “paroxystic and chronic polymorphous and pruri-
ginous dermatoses, Hebra's prurigo type.” Such a detailed
description of distribution, nature, clinical course, and response to
treatment of a rash can be applied in today's daily clinical
practice.1e4 AD is characterized by itch preceding dermatitis, and
symptoms and response to treatment are different in early infancy
and after childhood. Thus, elucidation of the distinctive mechanismvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Clinical characteristics of AD change with both age and disease duration. During early childhood, clinical manifestation is characterized with aggregated exudative papules or
small vesicles, so called eczematous change, accompanied by strong itch (left). These clinical features undergo age-related change. After childhood, skin manifestations change into
symmetrically localized extensive dermatitis with licheniﬁcation (right). This chronic skin condition occurs repeatedly where the itch ﬁrst appeared, and is referred to as
neurodermatitis.
Table 1
Major itch-inducing factors and their receptors in atopic dermatitis.
Ligands Receptors Ref.




H. Murota, I. Katayama / Allergology International 66 (2017) 8e13 9leading to itch related to AD for each age range is required.
Furthermore, itch related to AD is aggravated by heat, sweating,
wool ﬁbers, emotional stress, certain foods, alcohol, and the com-
mon cold.5 Especially the ﬁrst three are known to be related to
factors that aggravate clinical itch. Countermeasures of these
aggravating factors are essential for itch management of AD.Bradykinin Bradykinin receptors 28
Serotonin, 5-HT 5-HT receptor 29
Endothelin-1 Endothelin receptors (ETA) 30,31
IL-31 IL-31 receptor A 32
TSLP TSLP receptor 33
Substance P NK-1R 34,35
PAF PAF receptor 36






IL-2 IL-2 receptor 42
GRP GRP receptor 43,44
b-endorphin m opioid receptor 45,46
Acethylcholine Acethylcholine receptor 47
CGRP CGRP receptor 48
PAR, protease activated receptor; HT, hydroxytryptamine; TSLP, thymic stromal
lymphopoietin; NK-1R, neurokinin-1 receptor; PAF, platelet activating factor; LTB4,
leukotriene B4; GFR, glial cell line-derived neurotrophic factor receptor; 12-HPETE,
12-hydroperoxyeicosatetraenoic acid; GRP, gastrin releasing peptide; CGRP, calci-
tonin gene-related peptide.Transmission and processing of itch in AD
Itch is transmitted to the brain by electrical impulses and waves
passing through peripheral nerve ﬁbers. The brain receives the
information and induces a bodily reaction. Recently, it has been
indicated that astrogliosis in spinal dorsal horn inﬂuences chronic
itch in AD-like animal models, and that the processing of the sense
of itch, which is characteristic in AD, occurs in the central nerves.6
Further clariﬁcation of the speciﬁc mechanism of transmission of
the sense of itch in human AD is required. Here, the overall picture
of neuronal transmission of itch is summarized.
The itch-related stimuli from skin are received by the receptor in
the free nerve ending of the skin, then converted to electrical cur-
rent by coexisting ion channel, and is transmitted to the spinal cord.
Many receptors and ligands related to itch have been reported
previously (Table 1). Itch ligands (pruritogens) activate voltage
gated ion channels by exciting TRPV1 (histaminergic) or TRPA1
(non-histaminergic), and subsequently increase action potential
leading to an itch sensation.7e10 In recent years, TRPV1 and TRPA1
have been in the spotlight as targets for drug development because
they are keys to peripheral itch transmission.11 Inhibition of TRPV1
or TRPA1 can attenuate itch in AD-likemodel animals.12,13 Electrical
current occurring in the free nerve ending is transmitted to the
spinal cord. The electrical current from the peripheral nerve of the
skin is transmitted to neurons which travel to the central nerve via
interneurons in the spinal cord.7 Strength of the electrical current is
adjusted in the spinal cord and sorted by interneurons. The func-
tions of inhibitory interneurons are of particular interest.14e16
Scratching, heat stimulation, and mechanical stimulation on the
skin surface can inﬂuence itch-intensity. These stimulationsincrease inhibitory interneuron activity in the spinal cord via the
peripheral nerve which transmits the feeling of pain of the skin.
Neurotransmission inhibitors (neurotransmitter gamma-
aminobutyric acid (GABA)), glycine, and dynorphins are released
from the nerve ending of inhibitory interneurons, and control
neuron activity to the central nerve.15,16 As a result, itch will sub-
side. Controlling inhibitory interneurons is considered to be a
strong candidate as a strategy for itch treatment. This processed
itch signal is transmitted from the spinal cord through the neurons
in the ascending pathway to the amygdala via the thalamus or
medulla oblongata of the central nerve. The itch signal is analyzed
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as localization, quality, scratch, impact, pain, and pleasure.17,18
Processing of itch signals in the central nervous system was
found to differ in AD patients compared to healthy subjects.19 Up to
now, although the circuit in the central nerve has not been sufﬁ-
ciently clariﬁed, central nerves may contribute to control itch. The
descending noradrenergic system suppresses itch signaling by ac-
tion mediated by a(2)-adrenoceptor.20,21 Noradrenaline, which is
secreted in the process of the descending nerve system due to
excitability of the sympathetic neuron of the medulla or midbrain,
can exert tonic inhibition of itch.20,22 Hence, itch is controlled in the
signiﬁcant condition of the sympathetic nerve, such as daytime, or
when concentrating on something. Also, in AD subjects, itch can be
controlled when the attention of the patient is captured by some-
thing other than the itch. Further understanding of the descending
anti-pruritic nerve system is expected to contribute to improved
treatment of itch from AD.Itch due to dry skin or inﬂammation in AD
In skin symptoms such as eczema and dry skin, various sub-
stances which cause itch (pruritogens) such as cytokine and
chemical messengers are released from the affected area23,24
(Table 1, Fig. 2). Pruritogens induce itch mainly by acting on the
nerve, and the affected area is then scratched.24 However, skin le-
sions cannot be peeled from the skin, and such scratching aggra-
vates dermatitis. This vicious cycle is called the “itchescratch
cycle”. In chronic inﬂammation such as AD, skin hyperesthesia
occurs. Elongation of the sensory nerve in the epidermis up to right
under the stratum corneum due to drying and inﬂammation is also
considered to be a cause of skin hyperesthesia49 (Fig. 2). NGF,
semaphoring 3A, IL-31, and artemin are related to this aberrant
nerve elongation and sprouting in AD.41,50,51 Histamine derived
from degranulation of mast cells, and substance P which is released
from the nerve ending, act directly or indirectly on the aberrantlyFig. 2. Illustrating both trigger of itch and causes of neural sensitization schematically. Presu
may augment the susceptibility to these exacerbating factors for itch.elongated nerve, and cause itch. In addition, the role of inﬂam-
matory mediators, such as thymic stromal lymphopoietin (TSLP)
derived from epidermal keratinocytes and IL-31 derived from
inﬁltrated lymphocytes, on itch has been a recent topic. TSLP and
IL-31 were found to induce itch by acting directly on nerve ﬁ-
bers.32,33 In hepatic disorders, increase in autotaxins (lysophos-
pholipase) due to cholestasis has been found to cause itch.52
Furthermore, a correlation between autotaxin concentration in
the blood and itch intensity in subjects with AD has been
reported.53
Itch is sometimes induced, not from the skin, but from visual or
auditory information. For example, when a person sees an image
suggestive of itch, such as being bitten by a mosquito, or hears the
sound of somebody else scratching their skin, he may have the urge
to scratch himself54,55 (Fig. 2). This phenomenon is known as
“contagious itch”.56 In AD, “contagious itch” has been proven to be
stronger than that in healthy subjects.56 Psychological and mental
factors are also thought to inﬂuence itch. Although actual condi-
tions remain unclear, insomnia is also thought to contribute to the
onset and worsening of itch. The impact of insufﬁcient sleep and
the inﬂuence of the circadian rhythm on itch due to AD will be
described later.Temperature and itch
Patients with AD often complain that “itchiness increases when
it gets warm”.5,57 While “heat” has been known as major inducer of
itch in AD,5 there are still many uncertainties in its mechanism.
Furthermore, thermally-provoked itch frequently shows poor
treatment response.57 We can experience the relationship between
temperature and itch in daily life. For example, ordinarily, itch can
be relieved by a painful hot shower or cooling the itchy area with
ice. This phenomenon has been validated by scientiﬁc methods,
and suppression of histamine-evoked itch could be achieved by
heat or cold stimulation on healthy skin.19,58,59 However, itch in ADmably, memories from repeated experiences of itch may promote neural plasticity, and
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painful heat stimulation.19,58,60 In other words, AD may promote
abnormal hyperesthesia causing patients to feel thermal stimula-
tion as itch. This phenomenon is thought to occur due to sensiti-
zation of the peripheral or central nerve, and its molecular
mechanism has been slowly revealed.
Skin peripheral nerve ﬁbers are normally distributed in the
dermis surrounded with abundant ﬁbroblasts. From this, nerve ﬁ-
bers are assumed to be affected by factors secreted from dermal
ﬁbroblasts, and sensitized to cause alloknesis. Thus, we compre-
hensively analyzed genes expressed from dermal ﬁbroblasts which
were stimulated by factors related to allergic inﬂammation and
itch. As a result, we focused on artemin, a neurotrophic factor,
induced from dermal ﬁbroblast which was stimulated with sub-
stance P.41 Although, artemin is considered to be important mainly
in the development of sympathetic innervation, its function in skin
was unknown. Expression of artemin is not observed in normal
human skin, but is strongly deposited in dermal lesions of AD and
nummular eczema.41 Mice administered artemin showed an
increased number of peripheral sensory nerves in the skin, and
developed skin thermal hypersensibility. Furthermore, mice
administered artemin on their back skin displayed abnormal
behavior such as rubbing the skin of their whole body skin inwarm
temperature conditions at 38 C. This phenomenon was not
observed in the artemin receptor (GFRa3) knock out mice.
Abnormal accumulation of artemin in the local skin was thought to
cause systemic thermally-provoked itch. Now, the question re-
mains as to why accumulation of localized artemin affects skin
sensation of the whole body. Administration of capsazepine, a se-
lective antagonist of temperature receptor TRPV1, did not suppress
the abnormal behavior caused by artemin in a warm environment.
Thus, this reaction is currently thought to be caused by a mecha-
nism independent to TRPV1.41
In AD, even the temperature setting of the bathwater or of the
air conditioner should be considered. Actually, events in everyday
life and clinical practice provide us with opportunities to consider
the importance of temperature setting. For example, patients with
AD scratch an itch developed right after taking a hot bath, or scratch
their body right after taking off their clothes. These phenomena are
assumed to be related to rapid temperature change of the surface of
the skin. In fact, rapid change in skin surface temperature has been
experimentally conﬁrmed to increase itch. Pfab et al. stimulated
skin administered histamine by repeatedly alternating temperature
between warm (32 C) and comparatively cold (25 C) at 20 s in-
tervals, and found that itch was heightened by rapid change in skin
surface temperature.61 These results indicate that even within the
familiar temperature range of our daily life, rapid change in tem-
perature can intensify itch. AD patients should be instructed to
avoid extreme temperature settings for both the air conditioner
and bathwater. The Japanese guideline for AD recommends an
appropriate temperature of bathwater as 38e40 C.62
Perspiration and itch
Body temperature adjustment activity: Mammals are homeo-
thermic with a stable body temperature. When body temperature
increases, thermal control mechanisms, such as perspiration,
expiration, and heat transfer are activated.63 Humans have eccrine
sweat glands throughout the body and perspire to regulate body
temperature effectively. Perspiration is an important physiological
function to adjust body temperature in human activities.63
Sweat contains components to maintain skin homeostasis, such
as natural moisture-retaining factors (urea and sodium lactate),
bactericidal peptides (dermcidin, cathelicidin, b-defensin), and
secretory IgA to protect against infection.64 In addition, sweat hasan inhibiting effect on both cysteine protease activity and serine
protease activity, and contributes to the prevention of a proin-
ﬂammatory response against allergens with cysteine protease ac-
tivity, and to the formation of mature stratum corneum.65e68
Furthermore, it has been reported that sweat attenuates experi-
mentally induced itch intensity.69
On the other hand, sweat is known as an aggravating factor in
AD. Evidence in this regard, the mechanism of exacerbation of AD
by sweat can be largely divided to three categories,1) leaving excess
sweat on the skin without rinsing off, 2) abnormality in the com-
ponents of sweat, 3) abnormal decrease in perspiration. Perspira-
tion itself has been regarded as an aggravating factor due to the fact
that many patients with AD view sweating as an aggravating factor,
as seen in many large-scale self-completed questionnaires.70 In
addition, in a report indicating the existence of “sweat allergy”,
patient-derived basophils showed positive reaction in a histamine
release test for semipuriﬁed antigens extracted from sweat derived
from healthy subjects.71 On the other hand, Adachi et al. reported
that no positive reaction by sweat patch test was observed.72 Ac-
cording to the above reports, sweat itself is not considered to be
related to delayed allergic reaction, although it may be related in an
acute phase allergic reaction. It has been reported that the antigen
derived Malassezia globosa, an indigenous fungus involved in the
normal inhabitants of the skin, contaminated sweat, and may be
related to “sweat allergy”.73 Since fungal antigens are not primary
components of sweat, the merits and demerits of sweat on AD
should be discussed carefully. On the other hand, the possibility of
decreased antimicrobial components in perspiration is related to a
decrease in the ability to defend against infection of AD.64
In addition, abnormal decrease in perspiration ability with AD
has been indicated. Regarding its mechanism, A) perspiration is
produced but not discharged to the skin surface due to obstruction,
and B) abnormality occurs in the production and secretion of sweat
itself, etc., have been considered.64 One theory on the cause of
obstruction is the formation of a horny plug in the sweat pore.74
However, whether this is due to keratosis accompanied with
inﬂammation, or drying due to less sweating, is not conclusive.
Shiohara et al. conﬁrmed a leak image of dermcidin, a bactericidal
peptide contained in sweat, surrounding the sweat duct in the
lesion area of AD.75 As a result of sweat leaking outside the sweat
duct, the volume of sweat discharged to the skin surface decreases.
Next, in AD, decreased sweat secretion has been conﬁrmed by a
perspiration test using acetylcholine load and temperature
load.75e78 Regarding the mechanism, inﬂuence of autonomic dys-
tonia, and tendency of anxiogenic personality can be considered.77
In addition, we have recently discovered that histamine suppresses
perspiration by affecting the sweat gland.79 In other words, allergic
inﬂammation can be a cause of decreased perspiration in AD.
Decreased sweating in AD can be improved by treating the skin
symptoms. Therefore, improvement of impaired sweating should
be an important therapeutic outcome when determining man-
agement of AD.
Leaving excess sweat on the skin surface contributes to aggra-
vation of AD symptoms. One factor causing aggravation is a higher
pH level of skin surface due to neglected excess sweat.64 Ordinarily,
pH of insensible sweat, remains sufﬁciently low because sodium-
bicarbonate (HCO3
), and alkali ion, in sweat is reduced by reab-
sorption from the sweat duct.63 However, as the amount of sweat
increases with higher body temperature, reabsorption of HCO3

from the sweat duct fails, and sweat pH increases. If excess sweat
with higher pH remains on the skin, this may easily lead to
detachment of the horny cell layer, and increased susceptibility to
inﬂammation.64 Contamination or antigens (Malassezia-derived
antigens, etc.) contained in the sweat on the surface of the skin, and
may cause itch. Moreover, the merits of perspiration, such as
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excess sweat increases. Hence, in cases of itch accompanying
perspiration, old excess sweat should be washed or wiped off with
a wet towel.
The argument that sweat is an aggravating factor for AD can
easily lead to the short-sighted interpretation that “patients with
AD should not sweat.” However, there is no evidence that skin
symptoms improve under the guidance of “do not sweat”.80 Thus,
as mentioned above, improvement of impaired perspiration func-
tion can be a better treatment goal.Life rhythm and itch
Irregular habits lead to ﬂuctuation in the skin homeostasis. The
complaint “itch increases at night” is often heard from patients
with AD. In fact, deep body temperature shows diurnal variation,
increasing from the evening into the night, and is lowered by
dilatation of skin peripheral vessels during sleep.81 As a result, skin
temperature increases during sleep, and itch can easily occur.
Melatonin produced by the pineal gland is considered to be related
to decreased body temperature after sleeping. The habit of staying
up late reduces melatonin production, and inhibits the decrease of
deep body temperature81 (Fig. 2). Trans Epidermal Water Loss
(TEWL) is an indicator of skin barrier function and also increases at
night. As a result, in high-temperature and high-humidity (TEWL)
environments, the skin surface is susceptible to itch. Furthermore,
reduced cortisol production and increased IL-2 production, which
is related to inﬂammation, are observed during nighttime.81
Irregular habits will also cause imbalance in agonists for m-opioid
and k-opioid receptors, skewing toward susceptibility of itch.81Conclusion
Recent knowledge regarding factors related to the exacerbation
of itch, the mechanism of worsening conditions, and countermea-
sures of AD, have contributed to the management of AD. AD can be
aggravated by natural human physiological phenomena and our
living environment. Thus, providing a guidance policy for the pa-
tient is sometimes difﬁcult. Some problems still remain unresolved,
but we hope that the recent accumulation of evidence can be uti-
lized as much as possible in the guidance of patients.Conﬂict of interest
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